Tixagevimab/Cilgavimab Found Effective in Immunocompromised Veterans

The risk of COVID-19 morbidity and mortality is much higher for immunocompromised patients, and, while vaccines have been highly successful at preventing the spread of SARS-CoV-2 and decreasing the likelihood of severe disease in the general population, those who are immunocompromised still face a greater danger for breakthrough infections and persistent viral replication, according to a new study.